Source: International Congress 2015 – Interstitial lung diseases II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lutz Wollin (Biberach Riss, Germany), Jennifer Schuett, Angela Ostermann, Lutz Wollin. The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF. Eur Respir J 2015; 46: Suppl. 59, 3846

Member's Comments

No comment yet.

Related content which might interest you: Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 LATE-BREAKING ABSTRACT: Anti-fibrotic effects of nintedanib and pirfenidone in 2D versus 3D lung cultures Source: International Congress 2016 – IPF pathogenesis Year: 2016 Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 The efficacy of pirfenidone in scleroderma related interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Source: International Congress 2016 – IPF pathogenesis Year: 2016 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016